Survivin in brain tumors: an attractive target for immunotherapy

被引:11
|
作者
Masahito Katoh
Rick Wilmotte
Marie-Claude Belkouch
Nicolas de Tribolet
Gianpaolo Pizzolato
Pierre-Yves Dietrich
机构
[1] University Hospital of Geneva,Laboratory of Tumor Immunology, Division of Oncology
[2] University Hospital of Geneva,Department of Neurosurgery
[3] University Hospital of Geneva,Division of Neuropathology
[4] Hôpital Cantonal de Genève,Division d’oncologie, Laboratoire d’immunologie des tumeurs
关键词
apoptosis inhibitor; brain tumor; immunotherapy; survivin; tumor antigen;
D O I
10.1007/BF02700022
中图分类号
学科分类号
摘要
Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, bothin vitro andin vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.
引用
收藏
页码:71 / 76
页数:5
相关论文
共 50 条
  • [1] Survivin in brain tumors: an attractive target for immunotherapy
    Katoh, M
    Wilmotte, R
    Belkouch, MC
    de Tribolet, N
    Pizzolato, G
    Dietrich, PY
    JOURNAL OF NEURO-ONCOLOGY, 2003, 64 (01) : 71 - 76
  • [2] Survivin in Brain Tumors: An Attractive Target for Immunotherapy
    Masahito Katoh
    Rick Wilmotte
    Marie-Claude Belkouch
    Nicolas de Tribolet
    Gianpaolo Pizzolato
    Pierre-Yves Dietrich
    Journal of Neuro-Oncology, 2003, 64 : 71 - 76
  • [3] Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
    Rebecca Liu
    Duane A. Mitchell
    Cancer Immunology, Immunotherapy, 2010, 59 : 183 - 193
  • [4] Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
    Liu, Rebecca
    Mitchell, Duane A.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 183 - 193
  • [5] Immunotherapy in thymic epithelial tumors: an attractive dilemma
    Damaj, Nahed
    Nassar, Dany
    Chamaa, Bilal
    Kattan, Joseph
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 69 - 73
  • [6] Siglec-15: An Attractive Immunotherapy Target
    Poh, Alissa
    CANCER DISCOVERY, 2020, 10 (01) : 7 - 8
  • [7] Gpnmb/osteoactivin, an attractive target in cancer immunotherapy
    Zhou, L. T.
    Liu, F. Y.
    Li, Y.
    Peng, Y. M.
    Liu, Y. H.
    Li, J.
    NEOPLASMA, 2012, 59 (01) : 1 - 5
  • [8] Meloe: a new attractive target for melanoma immunotherapy
    Godet, Y.
    Moreau-Aubry, A.
    Vignard, V.
    Khammari, A.
    Dreno, B.
    Lang, F.
    Jotereau, F.
    Labarriere, N.
    2ND EUROPEAN CONGRESS OF IMMUNOLOGY (ECI), 2009, : 379 - 382
  • [9] Immunotherapy in brain tumors
    De Carli, Emilie
    Delion, Matthieu
    Rousseau, Audrey
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 117 - 126
  • [10] Immunotherapy for Brain Tumors
    Sampson, John H.
    Maus, Marcela V.
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (21) : 2450 - +